600518 Kangmei Pharmaceutical
- 1.85
- -0.01-0.54%
Kangmei Pharmaceutical News
Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price
Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) price-to-sales (or "P/S") ratio of 5.5x may not look like an appealing investment opportunity when you consider close to half the companies in the Phar
Kangmei Pharmaceutical Logs Profit in Q1
Kangmei Pharmaceutical (SHA:600518) returned to an attributable profit of 7.5 million yuan, or 0.001 yuan per share, in the first quarter, according to a Tuesday filing with the Shanghai Stock Exchang
ST Kangmei (600518.SH) announced first-quarter results, net profit of 7.4713 million yuan
ST Kangmei (600518.SH) released its report for the first quarter of 2024. The company achieved operating income of 1 during the reporting period...
The Strong Earnings Posted By Kangmei Pharmaceutical (SHSE:600518) Are A Good Indication Of The Strength Of The Business
Even though Kangmei Pharmaceutical Co., Ltd. (SHSE:600518 ) posted strong earnings, investors appeared to be underwhelmed. We have done some analysis and have found some comforting factors beneath th
Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) On An Uptrend: Could Fundamentals Be Driving The Stock?
Kangmei Pharmaceutical's (SHSE:600518) stock up by 6.1% over the past three months. Given that stock prices are usually aligned with a company's financial performance in the long-term, we decided to
Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4%
Kangmei Pharmaceutical (SHA:600518) returned to an attributable profit of 102.5 million yuan in 2023 from a loss of 2.69 billion yuan in 2022, according to a Monday filing with the Shanghai bourse. Ea
ST Kangmei (600518.SH) announced its 2023 annual results, with net profit of 103 million yuan, turning a loss into a profit
ST Kangmei (600518.SH) released its 2023 annual report. The company's revenue was 4.884 billion yuan,...
Court Dismisses Winding-Up Petition Against Kangmei Pharma's Unit
A Chinese court dismissed Foshan Xiangying Furniture Manufacturing's winding up petition against Kangmei Pharmaceutical's (SHA:600518) unit, Kangmei Traditional Chinese Medicine City (Puning), the pha
ST Kangmei (600518.SH) subsidiary Puning Chinese Pharmaceutical Market's bankruptcy and liquidation application was ruled inadmissible by the court
Zhitong Finance App News, ST Kangmei (600518.SH) issued an announcement. On March 13, 2024, the company disclosed the “Kangmei Pharmaceutical's Indicative Notice Concerning the Application for Bankruptcy and Liquidation of a Wholly-owned Subsidiary” (Notice Number: 2024-006). The creditor of Kangmei Chinese Medicine City (Puning) Co., Ltd. (hereinafter referred to as Puning Chinese Pharmaceutical Company or the respondent), revealed to Guangdong Province Intermediate Level on the grounds that Puning Chinese Pharmaceutical Company was unable to pay its debts due Proposed by the People's Court Bankruptcy liquidation application. Puning traditional Chinese medicine
Retail Investors Are Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥3.7b Last Week
Key Insights Significant control over Kangmei Pharmaceutical by retail investors implies that the general public has more power to influence management and governance-related decisions A total of 25
Is Kangmei Pharmaceutical (SHSE:600518) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious
Private Companies Own 32% of Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) Shares but Individual Investors Control 55% of the Company
Key Insights Kangmei Pharmaceutical's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors have a
The Past Five Years for Kangmei Pharmaceutical (SHSE:600518) Investors Has Not Been Profitable
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Anyone who held Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) for five years would be nursing thei
ST Kangmei (600518.SH) released the first three quarter results, with a net loss of 148 million yuan
ST Kangmei (600518.SH) released the report for the first three quarters of 2023, with the company's revenue of 3,534 billion...
ST Kangmei (600518.SH): Sales currently do not involve medicinal alcohol-related products
Glonghui September 15 | ST Kangmei (600518.SH) said on the investor interactive platform that the company achieved operating income of 2,377 billion yuan in the first half of 2023, an increase of 33.62% over the previous year, and net profit attributable to shareholders of listed companies was -126 million yuan, a year-on-year loss reduction of 35.67%. The business development situation in the first half of the year was steady, moderate and positive, and overall sales performance increased significantly and losses decreased significantly compared to last year. Up to now, the company has established in-depth business partnerships with more than 1,100 medical institutions and more than 40,000 pharmacy chains nationwide, and has a nationwide marketing layout. The company's core business is traditional Chinese medicine
ST Kangmei (600518.SH) released semi-annual results, with a net loss of 126 million yuan, narrower than the previous year
ST Kangmei (600518.SH) disclosed the 2023 semi-annual report. The company achieved revenue of 23.7 during the reporting period...
ST Kangmei (600518.SH): The court ruled that the applicant went bankrupt and liquidated the subsidiary Puning Chinese Pharmacy
According to the Zhitong Finance App, ST Kangmei (600518.SH) announced that Kangmei Chinese Pharmacy (Puning) Co., Ltd. (hereinafter referred to as Puning Traditional Chinese Pharmacy), a wholly-owned subsidiary of the company, received a “Civil Ruling” from the Jieyang Intermediate People's Court of Guangdong Province, ruling that Shenzhen Zhongkeheng Industrial Co., Ltd. (hereinafter referred to as Zhongke Heng or the applicant) would not accept the bankruptcy and liquidation application of the respondent Puning Chinese Pharmacy. Puning Traditional Chinese Pharmacy will continue to communicate with Zhongke Heng on debt matters. Since Puning Traditional Chinese Pharmacy has not yet entered bankruptcy and liquidation proceedings and continued to operate normally during this period, this matter will not affect the company's production and operation
Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) Stock Most Popular Amongst Retail Investors Who Own 54%, While Private Companies Hold 32%
Key Insights Kangmei Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 25 shareholders own 46% of
ST Kangmei (600518.SH): Wholly-owned subsidiary filed for bankruptcy and liquidation
On July 11, July 11丨ST Kangmei (600518.SH) announced that the company received a notice on July 10, 2023. Kangmei Chinese Pharmacy (Puning) Co., Ltd., a wholly-owned subsidiary of the company, received a “Notice” from the Guangdong Intermediate People's Court of Jieyang City (2023) Guangdong Province (2023) Guangdong Province, and Shenzhen Zhongkeheng Industrial Co., Ltd. filed a bankruptcy and liquidation application with the court on the grounds that Puning Traditional Chinese Pharmacy was unable to pay maturing debts.
Is Kangmei Pharmaceutical (SHSE:600518) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Analysis
Price Target
No Data
